Jul 18, 2022 7:00am EDT Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
Jun 02, 2022 8:00am EDT Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
May 12, 2022 7:00am EDT Unicycive Announces First Quarter Financial Results and Provides Business Update
Apr 14, 2022 7:10am EDT Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
Mar 31, 2022 7:00am EDT Unicycive Announces Full Year 2021 Financial Results and Provides Business Update
Mar 16, 2022 8:37am EDT Unicycive Announces Acceptance of Two Preclinical Data Sets to be Presented at the European Renal Association Congress
Feb 02, 2022 7:00am EST Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting
